GB9828511D0
(en)
|
1998-12-24 |
1999-02-17 |
Zeneca Ltd |
Chemical compounds
|
GB9919778D0
(en)
|
1999-08-21 |
1999-10-27 |
Zeneca Ltd |
Chemical compounds
|
CN1615873A
(en)
|
1999-12-24 |
2005-05-18 |
阿文蒂斯药物有限公司 |
Azaindoles compound
|
GB0004886D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004890D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004888D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004887D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0007371D0
(en)
|
2000-03-28 |
2000-05-17 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0016877D0
(en)
|
2000-07-11 |
2000-08-30 |
Astrazeneca Ab |
Chemical compounds
|
AU2001277621A1
(en)
*
|
2000-08-09 |
2002-03-04 |
Astrazeneca Ab |
Antiangiogenic bicyclic derivatives
|
GB0021726D0
(en)
|
2000-09-05 |
2000-10-18 |
Astrazeneca Ab |
Chemical compounds
|
SI1318997T1
(en)
*
|
2000-09-15 |
2006-12-31 |
Vertex Pharma |
Pyrazole compounds useful as protein kinase inhibitors
|
AU2001292670A1
(en)
|
2000-09-15 |
2002-03-26 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
ZA200301703B
(en)
*
|
2000-09-15 |
2004-03-02 |
Vertex Pharma |
Pyrazole compounds useful as protein kinase inhibitors.
|
US7473691B2
(en)
*
|
2000-09-15 |
2009-01-06 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
US6660731B2
(en)
*
|
2000-09-15 |
2003-12-09 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
ATE430742T1
(en)
*
|
2000-12-21 |
2009-05-15 |
Smithkline Beecham Corp |
PYRIMIDINAMINES AS ANGIOGENESIS MODULATORS
|
BR0116411A
(en)
*
|
2000-12-21 |
2003-11-11 |
Vertex Pharma |
Pyrazole compounds useful as protein kinase inhibitors
|
AU2006201228B2
(en)
*
|
2000-12-21 |
2010-01-28 |
Vertex Pharmaceuticals Incorporated |
Pyrazole Compounds Useful as Protein Kinase Inhibitors
|
US6756374B2
(en)
|
2001-01-22 |
2004-06-29 |
Hoffmann-La Roche Inc. |
Diaminothiazoles having antiproliferative activity
|
GB0103926D0
(en)
|
2001-02-17 |
2001-04-04 |
Astrazeneca Ab |
Chemical compounds
|
US7081454B2
(en)
|
2001-03-28 |
2006-07-25 |
Bristol-Myers Squibb Co. |
Tyrosine kinase inhibitors
|
GB0113041D0
(en)
|
2001-05-30 |
2001-07-18 |
Astrazeneca Ab |
Chemical compounds
|
GB0115109D0
(en)
|
2001-06-21 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
CA2452366A1
(en)
*
|
2001-06-29 |
2003-01-16 |
Ab Science |
Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
|
JP2005500041A
(en)
*
|
2001-06-29 |
2005-01-06 |
アブ サイエンス |
Potent, selective and non-toxic C-KIT inhibitor
|
DE60212627T2
(en)
*
|
2001-06-29 |
2007-06-14 |
Ab Science |
Use of tyrosine kinase inhibitors for the treatment of inflammatory diseases
|
DE60227709D1
(en)
*
|
2001-06-29 |
2008-08-28 |
Ab Science |
THE USE OF C-CRITERIA FOR THE TREATMENT OF AUTOIMMUNE DISEASES
|
EP1401413B1
(en)
|
2001-06-29 |
2006-11-22 |
AB Science |
Use of tyrosine kinase inhibitions for treating allergic diseases
|
JP2004537542A
(en)
*
|
2001-06-29 |
2004-12-16 |
アブ サイエンス |
Use of a tyrosine kinase inhibitor for treating inflammatory bowel disease (IBD)
|
US8101629B2
(en)
|
2001-08-13 |
2012-01-24 |
Janssen Pharmaceutica N.V. |
Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
|
JO3429B1
(en)
|
2001-08-13 |
2019-10-20 |
Janssen Pharmaceutica Nv |
Hiv inhibiting pyrimidines derivatives
|
US7638522B2
(en)
|
2001-08-13 |
2009-12-29 |
Janssen Pharmaceutica N.V. |
Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
|
US6939874B2
(en)
*
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
CA2461182A1
(en)
*
|
2001-09-20 |
2003-05-01 |
Ab Science |
Use of tyrosine kinase inhibitors for promoting hair growth
|
WO2003024386A2
(en)
*
|
2001-09-20 |
2003-03-27 |
Ab Science |
Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
|
WO2003026666A1
(en)
*
|
2001-09-26 |
2003-04-03 |
Bayer Pharmaceuticals Corporation |
2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors
|
NZ532593A
(en)
*
|
2001-10-25 |
2007-11-30 |
Wisconsin Alumni Res Found |
Vascular stent or graft coated or impregnated with protein tyrosine kinase inhibitors and method of using same
|
EP1448556A1
(en)
*
|
2001-11-01 |
2004-08-25 |
Janssen Pharmaceutica N.V. |
Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
|
SE0104140D0
(en)
|
2001-12-07 |
2001-12-07 |
Astrazeneca Ab |
Novel Compounds
|
GB0129476D0
(en)
*
|
2001-12-10 |
2002-01-30 |
Syngenta Participations Ag |
Organic compounds
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
US6797825B2
(en)
|
2001-12-13 |
2004-09-28 |
Abbott Laboratories |
Protein kinase inhibitors
|
TWI329105B
(en)
*
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
KR20040084896A
(en)
*
|
2002-02-06 |
2004-10-06 |
버텍스 파마슈티칼스 인코포레이티드 |
Heteroaryl compounds useful as inhibitors of gsk-3
|
AU2003209077A1
(en)
|
2002-02-08 |
2003-09-02 |
Smithkline Beecham Corporation |
Pyrimidine compounds
|
PT1478380E
(en)
*
|
2002-02-27 |
2006-12-29 |
Ab Science |
Use of tyrosine kinase inhibitors for treating cns disorders
|
GB0205693D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
WO2003076434A1
(en)
|
2002-03-09 |
2003-09-18 |
Astrazeneca Ab |
4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
|
GB0205688D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0205690D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
EP1485381B8
(en)
|
2002-03-15 |
2010-05-12 |
Vertex Pharmaceuticals Incorporated |
Azolylaminoazine as inhibitors of protein kinases
|
DE60332433D1
(en)
*
|
2002-03-15 |
2010-06-17 |
Vertex Pharma |
AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITOR
|
AU2003218215A1
(en)
*
|
2002-03-15 |
2003-09-29 |
Vertex Pharmaceuticals, Inc. |
Azolylaminoazines as inhibitors of protein kinases
|
CA2489648A1
(en)
*
|
2002-06-17 |
2003-12-24 |
Smithkline Beecham Corporation |
Chemical process
|
MY141867A
(en)
|
2002-06-20 |
2010-07-16 |
Vertex Pharma |
Substituted pyrimidines useful as protein kinase inhibitors
|
GB0215844D0
(en)
|
2002-07-09 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
US7517886B2
(en)
*
|
2002-07-29 |
2009-04-14 |
Rigel Pharmaceuticals, Inc. |
Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
|
EP2130541A3
(en)
*
|
2002-07-29 |
2013-12-18 |
Rigel Pharmaceuticals, Inc. |
Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
|
BR0313176A
(en)
*
|
2002-08-02 |
2005-06-14 |
Vertex Pharma |
Pyrazole compositions useful as gsk-3 inhibitors
|
CN101481356B
(en)
|
2002-08-09 |
2012-07-11 |
詹森药业有限公司 |
Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
|
EP1562935B1
(en)
*
|
2002-10-28 |
2006-09-06 |
Bayer HealthCare AG |
Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
|
US7109337B2
(en)
|
2002-12-20 |
2006-09-19 |
Pfizer Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
WO2004056807A1
(en)
|
2002-12-20 |
2004-07-08 |
Pfizer Products Inc. |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
US20040121968A1
(en)
*
|
2002-12-23 |
2004-06-24 |
Alexander Ljubimov |
Antiangiogenesis by inhibiting protein kinase CK2 activity
|
US7601718B2
(en)
*
|
2003-02-06 |
2009-10-13 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of protein kinases
|
ES2325440T3
(en)
|
2003-02-20 |
2009-09-04 |
Smithkline Beecham Corporation |
PIRIMIDINE COMPOUNDS.
|
GB0305929D0
(en)
*
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
US20050014753A1
(en)
*
|
2003-04-04 |
2005-01-20 |
Irm Llc |
Novel compounds and compositions as protein kinase inhibitors
|
GB0311276D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
GB0311274D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
JP2007516196A
(en)
*
|
2003-07-02 |
2007-06-21 |
ガラパゴス エヌブイ |
Pyrazine and pyralidine derivatives as Rho kinase inhibitors
|
US7312215B2
(en)
|
2003-07-29 |
2007-12-25 |
Bristol-Myers Squibb Company |
Benzimidazole C-2 heterocycles as kinase inhibitors
|
CN102358738A
(en)
|
2003-07-30 |
2012-02-22 |
里格尔药品股份有限公司 |
2,4-pyrimidinediamine compounds and uses of treating or preventing autoimmune diseases thereof
|
EP1648887A1
(en)
*
|
2003-07-30 |
2006-04-26 |
Cyclacel Limited |
Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
|
PL1660458T3
(en)
|
2003-08-15 |
2012-07-31 |
Novartis Ag |
2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
|
GB0321710D0
(en)
|
2003-09-16 |
2003-10-15 |
Novartis Ag |
Organic compounds
|
AU2004278413B2
(en)
*
|
2003-09-30 |
2008-07-31 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
CA2542522A1
(en)
|
2003-10-17 |
2005-05-06 |
Astrazeneca Ab |
4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer
|
US20050107374A1
(en)
*
|
2003-10-21 |
2005-05-19 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
MY141220A
(en)
*
|
2003-11-17 |
2010-03-31 |
Astrazeneca Ab |
Pyrazole derivatives as inhibitors of receptor tyrosine kinases
|
JP2007513184A
(en)
*
|
2003-12-04 |
2007-05-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Quinoxaline useful as an inhibitor of protein kinase
|
AU2005205118B2
(en)
*
|
2004-01-09 |
2009-02-26 |
Novartis Ag |
Phenyl-[4-(3-phenyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as IGF-IR inhibitors
|
WO2005068437A1
(en)
*
|
2004-01-16 |
2005-07-28 |
Novartis Ag |
2, 4 - diaminopyrimidines and their use for inducing cardiomyogenesis
|
TW200528101A
(en)
|
2004-02-03 |
2005-09-01 |
Astrazeneca Ab |
Chemical compounds
|
JP2007530453A
(en)
*
|
2004-03-19 |
2007-11-01 |
ザ ペン ステート リサーチ ファウンデーション |
Combinatorial methods and compositions for treating melanoma
|
PL2332940T3
(en)
|
2004-03-30 |
2013-03-29 |
Vertex Pharma |
Azaindoles useful as inhibitors of JAK and other protein kinases
|
US7211576B2
(en)
|
2004-04-20 |
2007-05-01 |
Hoffmann-La Roche Inc. |
Diaminothiazoles
|
BRPI0510980A
(en)
|
2004-05-14 |
2007-11-27 |
Pfizer Prod Inc |
pyrimidine derivatives for the treatment of abnormal cell growth
|
BRPI0511132A
(en)
|
2004-05-14 |
2007-11-27 |
Pfizer Prod Inc |
pyrimidine derivatives and pharmaceutical composition comprising the same
|
WO2005111016A1
(en)
|
2004-05-14 |
2005-11-24 |
Pfizer Products Inc. |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
CA2566531A1
(en)
|
2004-05-18 |
2005-12-15 |
Rigel Pharmaceuticals, Inc. |
Cycloalkyl substituted pyrimidinediamine compounds and their uses
|
PE20060664A1
(en)
|
2004-09-15 |
2006-08-04 |
Novartis Ag |
BICYCLE AMIDAS AS KINASE INHIBITORS
|
AU2005289426A1
(en)
*
|
2004-09-27 |
2006-04-06 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
US7776869B2
(en)
*
|
2004-10-18 |
2010-08-17 |
Amgen Inc. |
Heteroaryl-substituted alkyne compounds and method of use
|
GB2420559B
(en)
|
2004-11-15 |
2008-08-06 |
Rigel Pharmaceuticals Inc |
Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
|
EP1812424A4
(en)
|
2004-11-17 |
2009-07-08 |
Miikana Therapeutics Inc |
Kinase inhibitors
|
CA2584295C
(en)
|
2004-11-24 |
2014-08-26 |
Rigel Pharmaceuticals, Inc. |
Spiro-2, 4-pyrimidinediamine compounds and their uses
|
EP1841760B1
(en)
|
2004-12-30 |
2011-08-10 |
Exelixis, Inc. |
Pyrimidine derivatives as kinase modulators and method of use
|
DE602006010979D1
(en)
|
2005-01-19 |
2010-01-21 |
Rigel Pharmaceuticals Inc |
PRODRUGS FROM 2,4-PYRIMIDIN DIAMIN COMPOUNDS AND THEIR USES
|
RS52061B
(en)
|
2005-02-04 |
2012-04-30 |
Astrazeneca Ab |
Pyrazolylaminopyridine derivatives useful as kinase inhibitors
|
WO2006087530A1
(en)
|
2005-02-16 |
2006-08-24 |
Astrazeneca Ab |
Chemical compounds
|
WO2006091737A1
(en)
*
|
2005-02-24 |
2006-08-31 |
Kemia, Inc. |
Modulators of gsk-3 activity
|
BRPI0608252A2
(en)
|
2005-03-10 |
2010-04-06 |
Cgi Pharmaceuticals Inc |
chemical entities, pharmaceutical compositions comprising them, methods using said chemical entities and use of said chemical entities
|
EP1899323A2
(en)
|
2005-05-16 |
2008-03-19 |
AstraZeneca AB |
Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
|
WO2006129100A1
(en)
*
|
2005-06-03 |
2006-12-07 |
Glaxo Group Limited |
Novel compounds
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
WO2006133426A2
(en)
|
2005-06-08 |
2006-12-14 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
BRPI0613501A2
(en)
*
|
2005-07-01 |
2011-01-11 |
Irm Llc |
compound, pharmaceutical composition and use thereof
|
WO2007028445A1
(en)
*
|
2005-07-15 |
2007-03-15 |
Glaxo Group Limited |
6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives
|
PE20070362A1
(en)
*
|
2005-07-15 |
2007-04-23 |
Glaxo Group Ltd |
COMPOUNDS DERIVED FROM INDAZOLE-4-IL-2,4-PYRIMIDINDIAMINE AS INHIBITORS OF TYROSINE KINASE (KINASE Syk)
|
KR20080034483A
(en)
*
|
2005-07-26 |
2008-04-21 |
버텍스 파마슈티칼스 인코포레이티드 |
Benzimidazoles useful as inhibitors of protein kinases
|
US7737151B2
(en)
*
|
2005-08-18 |
2010-06-15 |
Vertex Pharmaceuticals Incorporated |
Pyrazine kinase inhibitors
|
AR056471A1
(en)
|
2005-08-24 |
2007-10-10 |
Wyeth Corp |
BAZEDOXIFEN ACETATE FORMULATIONS
|
CA2623374A1
(en)
|
2005-09-30 |
2007-04-05 |
Astrazeneca Ab |
Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
|
WO2007041358A2
(en)
|
2005-09-30 |
2007-04-12 |
Miikana Therapeutics, Inc. |
Substituted pyrazole compounds
|
GB0520958D0
(en)
*
|
2005-10-14 |
2005-11-23 |
Cyclacel Ltd |
Compound
|
BRPI0618011A2
(en)
|
2005-10-28 |
2011-08-16 |
Astrazeneca Ab |
compound or a pharmaceutically acceptable salt thereof, process for the preparation thereof, pharmaceutical composition, use of a compound or a pharmaceutically acceptable salt thereof, and methods for producing an antiproliferative effect and a pro-apoptotic effect in an animal warm-blooded to treat disease and to produce a jak inhibiting effect on a warm-blooded animal
|
US8604042B2
(en)
*
|
2005-11-01 |
2013-12-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
DK1951684T3
(en)
*
|
2005-11-01 |
2016-10-24 |
Targegen Inc |
BIARYLMETAPYRIMIDIN kinase inhibitors
|
US8133900B2
(en)
*
|
2005-11-01 |
2012-03-13 |
Targegen, Inc. |
Use of bi-aryl meta-pyrimidine inhibitors of kinases
|
CN101316843B
(en)
*
|
2005-11-03 |
2013-01-02 |
顶点医药品公司 |
Aminopyrimidines useful as kinase inhibitors
|
US7705009B2
(en)
|
2005-11-22 |
2010-04-27 |
Hoffman-La Roche Inc. |
4-aminopyrimidine-5-thione derivatives
|
BRPI0706537A2
(en)
|
2006-01-17 |
2011-03-29 |
Vertex Pharma |
azaindoles useful as janus kinases inhibitors
|
TW200736232A
(en)
*
|
2006-01-26 |
2007-10-01 |
Astrazeneca Ab |
Pyrimidine derivatives
|
WO2007085540A1
(en)
*
|
2006-01-27 |
2007-08-02 |
Glaxo Group Limited |
1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives
|
US20090069360A1
(en)
*
|
2006-03-16 |
2009-03-12 |
David Bryant Batt |
Organic Compounds
|
WO2007146981A2
(en)
*
|
2006-06-15 |
2007-12-21 |
Boehringer Ingelheim International Gmbh |
2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase c-alpha
|
US8222256B2
(en)
|
2006-07-05 |
2012-07-17 |
Exelixis, Inc. |
Methods of using IGFIR and ABL kinase modulators
|
JP5325783B2
(en)
|
2006-09-08 |
2013-10-23 |
エフ.ホフマン−ラ ロシュ アーゲー |
Benzotriazole kinase modulator
|
US20100048657A1
(en)
*
|
2006-09-12 |
2010-02-25 |
Cleveland State University |
Control of malignant cells proliferation through the inhibition of casein kinase 2
|
US20090054507A1
(en)
*
|
2006-09-12 |
2009-02-26 |
Cleveland State University |
Control of malignant cells by kinase inhibition
|
EP2086965B1
(en)
*
|
2006-11-02 |
2010-02-10 |
Vertex Pharmaceuticals, Inc. |
Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
|
WO2008063933A2
(en)
|
2006-11-10 |
2008-05-29 |
Massachusetts Institute Of Technology |
Pak modulators
|
AU2007328981B2
(en)
|
2006-12-08 |
2013-07-11 |
F. Hoffmann-La Roche Ag |
Substituted pyrimidines and their use as JNK modulators
|
AU2007333394C1
(en)
*
|
2006-12-08 |
2011-08-18 |
Novartis Ag |
Compounds and compositions as protein kinase inhibitors
|
EP3012249A1
(en)
|
2006-12-08 |
2016-04-27 |
Novartis AG |
Compounds and composition as protein kinase inhibitors
|
EP2099787B1
(en)
*
|
2006-12-19 |
2010-07-21 |
Vertex Pharmaceuticals, Inc. |
Aminopyrimidines useful as inhibitors of protein kinases
|
CA2679884A1
(en)
*
|
2007-03-09 |
2008-09-18 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as inhibitors of protein kinases
|
AU2008226461A1
(en)
|
2007-03-09 |
2008-09-18 |
Vertex Pharmaceuticals Incorporated |
Aminopyridines useful as inhibitors of protein kinases
|
NZ579485A
(en)
*
|
2007-03-09 |
2012-02-24 |
Vertex Pharma |
Aminopyrimidines useful as inhibitors of protein kinases
|
PT2137186E
(en)
*
|
2007-03-23 |
2016-03-30 |
Amgen Inc |
Heterocyclic compounds and their uses
|
CA2683785A1
(en)
|
2007-04-13 |
2008-10-23 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
WO2008128231A1
(en)
*
|
2007-04-16 |
2008-10-23 |
Hutchison Medipharma Enterprises Limited |
Pyrimidine derivatives
|
AU2008247592A1
(en)
|
2007-05-02 |
2008-11-13 |
Vertex Pharmaceuticals Incorporated |
Thiazoles and pyrazoles useful as kinase inhibitors
|
MX2009011812A
(en)
*
|
2007-05-02 |
2010-01-14 |
Vertex Pharma |
Aminopyrimidines useful as kinase inhibitors.
|
AU2008247595A1
(en)
*
|
2007-05-02 |
2008-11-13 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
MX2009012719A
(en)
*
|
2007-05-24 |
2010-02-04 |
Vertex Pharma |
Thiazoles and pyrazoles useful as kinase inhibitors.
|
US20090029992A1
(en)
*
|
2007-06-11 |
2009-01-29 |
Agoston Gregory E |
Substituted pyrazole compounds
|
CN101796046A
(en)
*
|
2007-07-16 |
2010-08-04 |
阿斯利康(瑞典)有限公司 |
Pyrimidine derivatives 934
|
AU2008282156B2
(en)
|
2007-07-31 |
2014-07-17 |
Vertex Pharmaceuticals Incorporated |
Process for preparing 5-fluoro-1H-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
|
WO2009032668A2
(en)
|
2007-08-28 |
2009-03-12 |
Irm Llc |
2 -biphenylamino-4 -aminopyrimidine derivatives as kinase inhibitors
|
WO2009065132A1
(en)
*
|
2007-11-16 |
2009-05-22 |
Oklahoma Medical Research Foundation |
Predicting and diagnosing patients with autoimmune disease
|
JP2011032169A
(en)
*
|
2007-12-11 |
2011-02-17 |
Genecare Research Institute Co Ltd |
4-aminopyrimidine derivative and medicinal composition containing the compound
|
WO2009111644A2
(en)
*
|
2008-03-05 |
2009-09-11 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating pancreatic cancer
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
AU2013205510A1
(en)
*
|
2008-05-21 |
2013-05-16 |
Ariad Pharmaceuticals, Inc. |
Phosphorous derivatives as kinase inhibitors
|
CA2723961C
(en)
*
|
2008-05-21 |
2017-03-21 |
Ariad Pharmaceuticals, Inc. |
Phosphorous derivatives as kinase inhibitors
|
CA2728729C
(en)
|
2008-06-23 |
2016-09-27 |
Vertex Pharmaceuticals Incorporated |
Protein kinase inhibitors
|
UY31929A
(en)
|
2008-06-25 |
2010-01-05 |
Irm Llc |
COMPOUNDS AND COMPOSITIONS AS CINASE INHIBITORS
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
BRPI0914682B8
(en)
|
2008-06-27 |
2021-05-25 |
Avila Therapeutics Inc |
heteroaryl compounds and compositions comprising said compounds
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
US20100016247A1
(en)
*
|
2008-07-21 |
2010-01-21 |
Florida State University Research Foundation |
Using budding yeast to screen for inhibitors of aurora kinases
|
AU2009288200A1
(en)
*
|
2008-09-03 |
2010-03-11 |
Vertex Pharmaceuticals Incorporated |
Co-crystals and pharmaceutical formulations comprising the same
|
CN104230901A
(en)
|
2008-09-15 |
2014-12-24 |
加利福尼亚大学董事会 |
Methods and compositions for modulating ire1, src, and abl activity
|
WO2010044103A1
(en)
*
|
2008-10-13 |
2010-04-22 |
National Institute Of Immunology |
Pharmaceutical composition for therapeutic or prophylactic treatment of bacterial infections and associated diseases
|
TW201022262A
(en)
*
|
2008-10-29 |
2010-06-16 |
Astrazeneca Ab |
Novel compounds 515
|
JO2885B1
(en)
|
2008-12-22 |
2015-03-15 |
ايلي ليلي اند كومباني |
Protein kinase inhibitors
|
CN102482277B
(en)
|
2009-05-05 |
2017-09-19 |
达纳-法伯癌症研究所有限公司 |
Epidermal growth factor receptor inhibitor and the method for treating obstacle
|
CN102459265A
(en)
*
|
2009-05-27 |
2012-05-16 |
雅培制药有限公司 |
Pyrimidine inhibitors of kinase activity
|
TW201100441A
(en)
|
2009-06-01 |
2011-01-01 |
Osi Pharm Inc |
Amino pyrimidine anticancer compounds
|
RS57869B1
(en)
|
2009-06-17 |
2018-12-31 |
Vertex Pharma |
Inhibitors of influenza viruses replication
|
US9573907B2
(en)
|
2009-11-02 |
2017-02-21 |
Snu R&Db Foundation |
2, 4-pyrimidine derivatives and use thereof
|
CA2780892C
(en)
*
|
2009-11-13 |
2017-02-14 |
Genosco |
Kinase inhibitors
|
EP2552211A4
(en)
*
|
2010-03-26 |
2013-10-23 |
Glaxo Group Ltd |
Indazolyl-pyrimidines as kinase inhibitors
|
WO2011120026A1
(en)
*
|
2010-03-26 |
2011-09-29 |
Glaxo Group Limited |
Pyrazolyl-pyrimidines as kinase inhibitors
|
KR20130099040A
(en)
|
2010-08-10 |
2013-09-05 |
셀진 아빌로믹스 리서치, 인코포레이티드 |
Besylate salt of a btk inhibitor
|
UY33549A
(en)
*
|
2010-08-10 |
2012-01-31 |
Glaxo Group Ltd |
QUINOLIL AMINAS AS INHIBITING AGENTS OF KINASES
|
BR112013010564B1
(en)
|
2010-11-01 |
2021-09-21 |
Celgene Car Llc |
HETEROCYCLIC COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME
|
JP5956999B2
(en)
|
2010-11-01 |
2016-07-27 |
セルジーン アヴィロミクス リサーチ, インコーポレイテッド |
Heteroaryl compounds and uses thereof
|
WO2012060847A1
(en)
|
2010-11-07 |
2012-05-10 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
ES2665013T3
(en)
|
2010-11-10 |
2018-04-24 |
Celgene Car Llc |
EGFR selective mutant inhibitors and uses thereof
|
PT2646448T
(en)
|
2010-11-29 |
2017-10-04 |
Osi Pharmaceuticals Llc |
Macrocyclic kinase inhibitors
|
KR20140014110A
(en)
|
2010-12-16 |
2014-02-05 |
버텍스 파마슈티칼스 인코포레이티드 |
Inhibitors of influenza viruses replication
|
CA2829131C
(en)
|
2011-03-04 |
2018-11-20 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Amino-quinolines as kinase inhibitors
|
KR20130131461A
(en)
*
|
2011-03-07 |
2013-12-03 |
폰다지오네 텔레톤 |
Tfeb variants and uses thereof
|
CN103501612B
(en)
*
|
2011-05-04 |
2017-03-29 |
阿里亚德医药股份有限公司 |
The compound that cell is bred in cancer caused by suppression EGF-R ELISA
|
CA2839937C
(en)
|
2011-07-05 |
2020-11-03 |
Vertex Pharmaceuticals Incorporated |
Processes and intermediates for producing azaindoles
|
EP2755939A4
(en)
|
2011-07-14 |
2015-04-15 |
Keith R Latham |
Halogenated phenols for diagnostics, antioxidant protection and drug delivery
|
ES2671748T3
(en)
|
2011-07-21 |
2018-06-08 |
Tolero Pharmaceuticals, Inc. |
Heterocyclic protein kinase inhibitors
|
UA118010C2
(en)
|
2011-08-01 |
2018-11-12 |
Вертекс Фармасьютікалз Інкорпорейтед |
INFLUENCES OF INFLUENZA VIRUS REPLICATION
|
TWI547494B
(en)
|
2011-08-18 |
2016-09-01 |
葛蘭素史克智慧財產發展有限公司 |
Amino quinazolines as kinase inhibitors
|
WO2013033862A1
(en)
*
|
2011-09-05 |
2013-03-14 |
浙江海正药业股份有限公司 |
4-substituted-(3-substituted-1h-pyrazole-5-amino)-pyrimidine derivatives having activity of inhibiting protein kinase and use thereof
|
PE20141581A1
(en)
*
|
2011-09-27 |
2014-11-14 |
Novartis Ag |
3-PIRMIDIN-4-IL-OXAZOLIDIN-2-ONAS AS INHIBITORS OF MUTANT HDI
|
US9364476B2
(en)
|
2011-10-28 |
2016-06-14 |
Celgene Avilomics Research, Inc. |
Methods of treating a Bruton's Tyrosine Kinase disease or disorder
|
KR101401664B1
(en)
*
|
2011-11-15 |
2014-06-11 |
중앙대학교 산학협력단 |
Novel pyrimidine-2,4-diamine derivatives for differentiation of neural stem cells and medical use thereof
|
UY34632A
(en)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
OXAZOLIDIN- 2- ONA COMPOUNDS AND USES OF THE SAME
|
EP2825042B1
(en)
|
2012-03-15 |
2018-08-01 |
Celgene CAR LLC |
Salts of an epidermal growth factor receptor kinase inhibitor
|
BR112014022789B1
(en)
|
2012-03-15 |
2022-04-19 |
Celgene Car Llc |
Solid forms of an epidermal growth factor receptor kinase inhibitor, pharmaceutical composition and uses thereof
|
WO2013169401A1
(en)
|
2012-05-05 |
2013-11-14 |
Ariad Pharmaceuticals, Inc. |
Compounds for inhibiting cell proliferation in egfr-driven cancers
|
WO2013192128A1
(en)
|
2012-06-20 |
2013-12-27 |
Merck Sharp & Dohme Corp. |
Imidazolyl analogs as syk inhibitors
|
EP2863914B1
(en)
*
|
2012-06-20 |
2018-10-03 |
Merck Sharp & Dohme Corp. |
Pyrazolyl derivatives as syk inhibitors
|
TW201425307A
(en)
|
2012-09-13 |
2014-07-01 |
Glaxosmithkline Llc |
Amino-quinolines as kinase inhibitors
|
TWI592417B
(en)
|
2012-09-13 |
2017-07-21 |
葛蘭素史克智慧財產發展有限公司 |
Prodrugs of amino quinazoline kinase inhibitor
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
CA2891412A1
(en)
|
2012-11-20 |
2014-05-30 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
|
CN104918919A
(en)
|
2012-11-21 |
2015-09-16 |
Ptc医疗公司 |
Substituted reverse pyrimidine bmi-1 inhibitors
|
US9512136B2
(en)
*
|
2012-11-26 |
2016-12-06 |
Universal Display Corporation |
Organic electroluminescent materials and devices
|
WO2014100748A1
(en)
|
2012-12-21 |
2014-06-26 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
US9145387B2
(en)
|
2013-02-08 |
2015-09-29 |
Celgene Avilomics Research, Inc. |
ERK inhibitors and uses thereof
|
WO2014128622A1
(en)
|
2013-02-21 |
2014-08-28 |
Glaxosmithkline Intellectual Property Development Limited |
Quinazolines as kinase inhibitors
|
AU2014229283B2
(en)
*
|
2013-03-14 |
2016-07-28 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
|
ES2665619T3
(en)
|
2013-03-14 |
2018-04-26 |
Novartis Ag |
3-Pyrimidin-4-yl-oxazolidin-2-ones as mutant HDI inhibitors
|
US10202356B2
(en)
*
|
2013-03-14 |
2019-02-12 |
Tolero Pharmaceuticals, Inc. |
JAK2 and ALK2 inhibitors and methods for their use
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
WO2014181813A1
(en)
*
|
2013-05-10 |
2014-11-13 |
武田薬品工業株式会社 |
Heterocyclic compound
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
US10370371B2
(en)
|
2013-08-30 |
2019-08-06 |
Ptc Therapeutics, Inc. |
Substituted pyrimidine Bmi-1 inhibitors
|
SI3068782T1
(en)
|
2013-11-13 |
2018-10-30 |
Vertex Pharmaceuticals Incorporated |
Methods of preparing inhibitors of influenza viruses replication
|
JP6615755B2
(en)
|
2013-11-13 |
2019-12-04 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Inhibitors of influenza virus replication
|
EP3071553A4
(en)
|
2013-11-21 |
2017-08-02 |
PTC Therapeutics, Inc. |
Substituted pyridine and pyrazine bmi-1 inhibitors
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
US10005760B2
(en)
|
2014-08-13 |
2018-06-26 |
Celgene Car Llc |
Forms and compositions of an ERK inhibitor
|
PT3604294T
(en)
*
|
2014-10-13 |
2021-07-29 |
Yuhan Corp |
Compounds and compositions for modulating egfr mutant kinase activities
|
CN111170998B
(en)
*
|
2014-11-05 |
2023-04-11 |
益方生物科技(上海)股份有限公司 |
Pyrimidine or pyridine compound, preparation method and medical application thereof
|
US10202365B2
(en)
|
2015-02-06 |
2019-02-12 |
Blueprint Medicines Corporation |
2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
|
EP3273955A4
(en)
*
|
2015-03-23 |
2019-05-01 |
The University of Melbourne |
Treatment of respiratory diseases
|
JP6857617B2
(en)
|
2015-05-13 |
2021-04-14 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Influenza virus replication inhibitor
|
EP3294717B1
(en)
|
2015-05-13 |
2020-07-29 |
Vertex Pharmaceuticals Inc. |
Methods of preparing inhibitors of influenza viruses replication
|
RU2734849C2
(en)
*
|
2015-07-16 |
2020-10-23 |
Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. |
Aniline pyrimidine derivatives and use thereof
|
CN105061506B
(en)
*
|
2015-07-27 |
2017-08-29 |
苏州明锐医药科技有限公司 |
Antineoplastic AP26113 preparation method
|
PT3371171T
(en)
|
2015-11-02 |
2024-01-24 |
Blueprint Medicines Corp |
Inhibitors of ret
|
CN106699810A
(en)
*
|
2015-11-17 |
2017-05-24 |
清华大学 |
Nitrogen-containing heterogeneous ring compound, preparation method thereof and application of nitrogen-containing heterogeneous ring compound in inhibition of kinase activity
|
EP3405196B1
(en)
|
2016-01-22 |
2019-12-04 |
Janssen Pharmaceutica NV |
New substituted cyanoindoline derivatives as nik inhibitors
|
AU2017208555B2
(en)
|
2016-01-22 |
2021-03-18 |
Janssen Pharmaceutica Nv |
New 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors
|
US20190060286A1
(en)
|
2016-02-29 |
2019-02-28 |
University Of Florida Research Foundation, Incorpo |
Chemotherapeutic Methods
|
WO2017161269A1
(en)
|
2016-03-17 |
2017-09-21 |
Blueprint Medicines Corporation |
Inhibitors of ret receptor tyrosine kinases
|
AU2017289317B2
(en)
|
2016-06-30 |
2021-04-01 |
Janssen Pharmaceutica Nv |
Cyanoindoline derivatives as NIK inhibitors
|
AU2017289315B2
(en)
|
2016-06-30 |
2021-04-01 |
Janssen Pharmaceutica Nv |
Heteroaromatic derivatives as NIK inhibitors
|
WO2018017983A1
(en)
*
|
2016-07-22 |
2018-01-25 |
Blueprint Medicines Corporation |
Compounds useful for treating disorders related to ret
|
WO2018022761A1
(en)
|
2016-07-27 |
2018-02-01 |
Blueprint Medicines Corporation |
Substituted cyclopentane-amides for treating disorders related to ret
|
WO2018118793A1
(en)
*
|
2016-12-19 |
2018-06-28 |
Isocure Biosciences Inc. |
Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof
|
AU2019247766A1
(en)
|
2018-04-03 |
2020-10-15 |
Blueprint Medicines Corporation |
RET inhibitor for use in treating cancer having a RET alteration
|
MX2020010437A
(en)
|
2018-04-05 |
2021-01-29 |
Sumitomo Pharma Oncology Inc |
Axl kinase inhibitors and use of the same.
|
US20210113562A1
(en)
|
2018-04-13 |
2021-04-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
|
CN108864052A
(en)
*
|
2018-06-07 |
2018-11-23 |
福建医科大学 |
A kind of synthesis and application of the fluorescence probe for GC33-3-1 antibody with specific recognition
|
CA3103995A1
(en)
|
2018-07-26 |
2020-01-30 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
EP3924351A4
(en)
|
2019-02-12 |
2022-12-21 |
Sumitomo Pharma Oncology, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
WO2020168197A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
|
WO2020180959A1
(en)
|
2019-03-05 |
2020-09-10 |
Incyte Corporation |
Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
|
US11919904B2
(en)
|
2019-03-29 |
2024-03-05 |
Incyte Corporation |
Sulfonylamide compounds as CDK2 inhibitors
|
WO2020223469A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
|
US11447494B2
(en)
|
2019-05-01 |
2022-09-20 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
CN116348458A
(en)
|
2019-08-14 |
2023-06-27 |
因赛特公司 |
Imidazolylpyrimidinylamine compounds as CDK2 inhibitors
|
CN110669038B
(en)
*
|
2019-09-21 |
2020-10-30 |
温州医科大学 |
Pyrimidine FGFR4V550LInhibitor, preparation method and application thereof
|
CN110746402B
(en)
*
|
2019-09-21 |
2021-01-15 |
温州医科大学 |
2-N-aryl-4-N-aryl-5-fluoropyrimidine compound and preparation method and application thereof
|
US11851426B2
(en)
|
2019-10-11 |
2023-12-26 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|